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a b s t r a c t
Reactivation of latent herpes simplex virus 2 (HSV-2) infections can be characterized by episodic
recurrent genital lesions and/or viral shedding. We hypothesize that infected (HSV-2pos) asymptomatic
individuals have acquired T cell responses to speciﬁc HSV-2 antigen(s) that may be an important factor in
controlling their recurrent disease symptoms. Our proteomic screening technology, ATLAS™, was used
to characterize the antigenic repertoire of T cell responses in infected (HSV-2pos) and virus-exposed
seronegative (HSV-2neg) subjects. T cell responses, determined by IFN-γ secretion, were generated to gL,
UL2, UL11, UL21, ICP4, ICP0, ICP47 and UL40 with greater magnitude and/or frequency among cohorts of
exposed HSV-2neg or asymptomatic HSV-2pos individuals, compared to symptomatic recurrent HSV-2pos
subjects. T cell antigens recognized preferentially among individuals who are resistant to infection or
who are infected and have mild or no clinical disease may provide new targets for the design of vaccines
aimed at treating and/or preventing HSV-2 infection.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Genital infection with HSV is characterized by the development
of painful ulcers that spontaneously resolve. The virus remains in
the dorsal root ganglia of the sacral nerves but re-emerges causing
clinical recurrences at variable intervals and with variable severity.
With over 500 million existing infections, and 20 million new
cases per year, herpes simplex virus type 2 (HSV-2) is a worldwide
pandemic (Looker and Garnett, 2005). Until an effective vaccine is
developed, those numbers are expected to grow. Considerable
time and resources have been devoted to developing vaccines for
the immunotherapy or prophylaxis of HSV-2. All vaccines tested to
date have failed to meet pre-deﬁned endpoints in clinical trials.
Studies conducted in mice suggest that control of HSV-2 will
require coordinated immune responses, including both antibody
production and activation of CD4þ and CD8þ T cells (Morrison et al.,
2001; Thebeau and Morrison, 2003). A clinical trial of a vaccine
targeting the HSV-2 surface glycoproteins D and B (gD2 and gB2)
and adjuvanted with MF59 successfully activated CD4þ T cells and
neutralizing antibody production (Corey, 1999). Nevertheless, vacci-
nation failed to prevent acquisition of HSV-2 infection, and had no
impact on clinical symptoms following primary infection or on
subsequent frequency of reactivation. gD and gB have been shown
to be important targets of neutralizing antibody responses to
infection but their role as protective T cell antigens in humans has
not been established. The latest HSV-2 clinical trial with its focus on
the subgroup of double seronegative women, showed that the gD2
subunit vaccine adjuvanted with aluminum hydroxide and 3-O-
deacylated monophosphoryl lipid Awas effective in preventing HSV-
1 genital disease or infection but not in preventing HSV-2 disease or
infection (Belshe et al., 2012). Recently, Belshe et al. demonstrated a
statistically signiﬁcant correlation between gD antibody concentra-
tion and efﬁcacy (Belshe et al., 2013). These clinical trial outcomes,
along with ﬁndings from animal disease models (Morrison et al.,
2001; Thebeau and Morrison, 2003) suggest a critical role for
antibody and T cells with diverse speciﬁcities in controlling HSV-2
infection, and that incorporating antigens capable of activating
CD8þ T cell responses in addition to CD4þ T cell responses and
antibody will be essential for eliciting a protective immune response.
In addition, it will be necessary to deliver these antigens with an
adjuvant or delivery system that stimulates appropriate humoral
and cellular immune responses.
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The clinical course of HSV-2-induced genital disease is varied.
While the majority of seropositive individuals remain asympto-
matic, others experience frequent recurrent outbreaks. Clearance
of HSV-2 from genital herpes lesions has been associated with an
inﬂux of HSV-speciﬁc CD8þ T cells, and it has been proposed that
these cells play a role in immune control of symptomatic HSV-2
reactivation in genital skin (Koelle et al., 2001, 1998; Zhu et al.,
2007). Several recent studies have demonstrated that T cells
isolated from asymptomatic versus symptomatic subjects exhibit
differential epitope speciﬁcity, implying that antigens that prefer-
entially activate T cells of asymptomatic HSV-2 carriers may play a
crucial role in controlling disease (Chentouﬁ et al., 2008; Dasgupta
et al., 2012). In this study we use full-length or large protein
fragments rather than peptides to screen T cells for potential
differences between asymptomatic and symptomatic cohorts; as
a result, differences at the epitope level may be missed. Recently,
Johnston et al. (2014) used a HSV-2 (ORF)eome expression library
to test for proliferative CD4þ T cell responses in genital biopsy
specimens of HSV-2 seropositive subjects. However, the focus of
this study is the characterization of both CD4þ and CD8þ
peripheral T cell antigen repertoires in HSV-2 seropositive and
seronegative cohorts across a broad population, rather than a
search for more restricted differences at an epitope level or the
dissection of antigen-speciﬁc T cell responses at mucosal surfaces.
Interestingly, Posavad et al. demonstrated that some individuals
who are HSV seronegative elicited peripheral HSV-speciﬁc T cell
responses despite the absence of infection, suggesting that virus-
speciﬁc T cells in these individuals have been stimulated by
exposure and provide protection (Posavad et al., 2010). The
rational design of a vaccine that mimics this response could
potentially control disease.
Identiﬁcation of antigens, especially those to which CD8þ T
cells can respond, has been complicated by the multiple restric-
tions of epitope presentation in genetically diverse individuals and
the requirement that proteins are processed through the cytosolic
route of antigen presentation. Recent approaches to identify CD8þ
T cell antigens include in silico epitope prediction (Moutaftsi et al.,
2006), generation of overlapping peptides targeting a portion of a
pathogen's proteome (Braun et al., 2006; Hosken et al., 2006), and
screens of random genomic libraries expressed by mammalian
cells (Koelle, 2003; Starnbach et al., 2003). One major limitation of
these approaches is the failure to identify antigens capable of
being presented by the numerous HLA class I haplotypes repre-
senting a diverse human population. In addition, these screens do
not guarantee comprehensive coverage of the entire pathogen
proteome, excluding potentially relevant antigens. Indeed, the
high cost of synthesizing numerous overlapping peptides gener-
ally limits the possibility of including the entire proteome. The
microbial genomic approach does have the potential to provide
complete coverage of the genome by translation of non-annotated
ORFs and out-of-frame products. In contrast, our library platform
is built using annotated ORFs and therefore does not necessarily
include undocumentated ORFs, although it is possible that tran-
scriptional variants are generated within the E. coli expression
constructs.
The HSV-2 genome encodes 74 unique open reading frames
(Dolan et al., 1998), accounting for potentially hundreds of T cell
epitopes. We hypothesize that identiﬁcation of HSV-2 proteins
that correlate with clinical evidence of protection against disease
in individuals who have been naturally exposed to virus, greatly
enhances the odds of developing a successful vaccine candidate by
signiﬁcantly narrowing the ﬁeld of potential antigens. To uncover
these speciﬁc T cell antigens from a large pool of protein candi-
dates, we created a high throughput, proteomic technology that
facilitates unbiased and comprehensive identiﬁcation of both
CD4þ and CD8þ T cell antigens. This antigen screening system
has been used previously to identify CD4þ T cell antigens from
S. pneumoniae (Li et al., 2012; Mofﬁtt et al., 2011), and CD4þ and
CD8þ T cell antigens from C. trachomatis (Picard et al., 2012; Roan
et al., 2006) and P. falciparum (unpublished data). This method
consists of two components: (1) bacterial libraries, expressing
cLLO (cytoplasmic variant of listeriolysin O) for CD8þ T cell
screening and without cLLO expression for CD4þ T cell screening,
comprising all proteins predicted to be expressed by the pathogen;
and (2) an in vitro immunological screening system that allows
discernment of which antigens are capable of inducing the most
potent T cell responses in human cells.
In this study, we built a complete HSV-2 proteomic library and
screened it with CD8þ and CD4þ T cells from a total of 147 HSV-2-
infected and uninfected individuals to identify viral antigens that
elicited IFN-γ secretion. Nomination of viral antigens for further
development as vaccine candidates is based on difference in
responses to antigens among individuals who control the disease
or resist infection (“protected”) and those who do not (“unpro-
tected”). The data were analyzed with three main foci: 1) deter-
mination of the overall frequency with which individuals respond
to HSV-2-derived antigens; 2) evaluation of differences in fre-
quency of responses between “protected” and “unprotected”
individuals; and 3) evaluation of differences in the magnitude of
responses between cohorts. Analysis of human cohorts displaying
a spectrum of clinical phenotypes to HSV-2 infection has identiﬁed
protein antigens able to induce T cells targeting HSV-2 which
correlate with control of infection and/or disease.
Results
Clinical and demographic characteristics of cohorts
Of the 147 subjects recruited into the study, 92 were HSV-2pos
and 55 were HSV-2neg. The HSV-2pos subjects were categorized
according to recurrence frequency, and distributed into two main
cohorts: 52 who were symptomatic, with a median of ﬁve
recurrences per year, which were deﬁned as “unprotected”; and
40 who had a documented primary outbreak but reported no
known recurrences since, who were characterized as asympto-
matic, and deﬁned as “protected” (Table 1). The recurrers could be
further broken out into those who had frequent (four or more) and
those with infrequent recurrences (less than four) annually. The
symptomatic cohort had a median age of 38 years, with 71%
female; the asymptomatic cohort had a median age of 34 years,
with 61% female. Fifty-ﬁve subjects were HSV-2neg, of whom 37
were characterized as “exposed”, due to an ongoing sexual
relationship with HSV-2pos partners and who were also deﬁned
as “protected”. Eighteen HSV-2neg subjects had no known expo-
sure to HSV-2, thus were deﬁned as “unexposed”. The median age
of the exposed cohort was 38 years, with 46% female, while that of
the unexposed cohort was 29 years of age, with 67% female. As
part of the recruitment criteria, none of the HSV-2pos subjects
were seropositive for HSV-1 (HSV-1pos); however 32 of 55 HSV-
2neg subjects were HSV-1pos (23 HSV-2 exposed and 9 unexposed).
To rule out the possibility that one HLA class I supertype was
overrepresented in respective “protected” (i.e. exposed seronega-
tive) and “unprotected” (i.e. HSV-2pos symptomatic) cohorts
(Supplementary Table 2), we examined the distribution of the
nine deﬁned HLA class I supertypes among subjects representing
each group (Sette and Sidney, 1999; Sidney et al., 2008). Eight of
the nine deﬁned supertypes were present in the population sent
for typing; one supertype, HLA-B62, was absent. As shown in
Supplementary Table 2, chi-squared tests comparing 19 HSV-2neg
exposed, 20 HSV-2pos protected (asymptomatic) subjects and 31
HSV-2pos unprotected (symptomatic) individuals showed no
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statistically signiﬁcant pattern of HLA class I haplotype frequency,
although the power to detect differences is low in this small
sample.
Relationship of antibody responses with clinical phenotype
To determine if antibody responses correlated with the reported
clinical phenotypes, we examined the plasma antibody titers against
gD2 and HSV-2-neutralizing antibodies in all study participants. As
shown in Fig. 1, subjects deﬁned as seropositive for either HSV-2 or
HSV-1 (HSV-2pos/1neg; HSV-2neg/1pos) demonstrated robust antibody
titers to gD2 protein by ELISA and measurable HSV-2 neutralizing
antibody titers, as expected because of the high amino acid homology
between HSV-1 and HSV-2 gD. There was a statistically signiﬁcant
difference in the gD-speciﬁc and virus neutralizing titers between
asymptomatic and symptomatic HSV-2pos donors (Fig.1A and B), with
higher antibody titers present in symptomatic compared with asymp-
tomatic HSV-2 infected individuals. Plasma antibody titers to gD were
at or below the limit of detection for 8 of the 9 subjects believed to be
unexposed to HSV (HSV-2neg/1neg), and for 12 out of 14 who were
HSV-2-exposed (HSV-2neg/1neg). Similarly, 18 of 23 subjects (78%) who
were HSV-2neg/1neg had no measurable HSV-2 neutralizing antibody
titers, compared to 21 of 124 (17%) of those who were HSV-
seropositive. There were no statistically signiﬁcant differences in the
neutralizing titers for the exposed HSV-2neg/1pos subjects compared
with the unexposed HSV-2neg/1pos volunteers, as expected (Fig. 1B).
Two subjects (exposed) serotyped as HSV-2neg/1neg by the HerpeSelect
ELISA showed both measurable gD2 titers and neutralizing antibodies
against HSV-2.
Generation and validation of the HSV-2 proteomic expression library
An HSV-2 proteomic expression library was constructed to identify
proteins across the entire HSV-2 proteome which correlate with high-
frequency, protective immune T cell responses in individuals exposed
to virus. To this end, 75 annotated viral genes, including UL43.5 which
is antisense to UL43 (Dolan et al., 1998; Ward et al., 1996), were PCR-
ampliﬁed or synthetically built and cloned into an E. coli expression
vector, resulting in the insertion of an in-frame C-terminal OVA257-264
(SIINFEKL) epitope tag that was used to conﬁrm the expression of each
full-length or truncated protein in the HSV-2 library by a high-
throughput T cell hybridoma assay (Fig. 2A) (Shastri and Gonzalez,
1993). This analysis conﬁrmed successful cloning, expression, and
MHC class I presentation of all 75 putative HSV-2 genes, either as full-
length or fragmented proteins. The levels of expression relative to the
positive control varied from low (r25%) to high (Z75%), depending
on the clone. Prior studies have demonstrated that proteins expressed
at even levels below the sensitivity of Western Blots are capable of
yielding a positive response in T cell screens (Gierahn, 2007).
To determine which antigens within the HSV-2 proteome induce
potent T cell activation, sorted CD4þ and CD8þ T cells from each
donor were used to screen the HSV-2 protein library. A schematic of
the T cell screening protocol is shown in Fig. 2B. Fig. 2C shows
representative IFN-γ responses from CD8þ T cells obtained from an
asymptomatic HSV-2pos subject, after stimulation with the HSV-2
proteomic library. IFN-γ levels across the library ranged from o1 to
120 pg/ml; the average response to the negative control clone
expressing green ﬂuorescent protein (GFP) was 4 pg/ml and the
positive control, phytohemagglutinin (PHA), response was 1732 pg/
ml (data not shown). Analysis of CD4þ and CD8þ T cell IFN-γ
responses to UL1 (gL2), UL19 (VP5), RS1.2 (ICP4.2) and Us6 (gD2)
overlapping peptides for 9 HSV-2pos and HSV-2neg subjects by ELISPOT
demonstrated overlap with our ATLAS™ screening results
(Supplementary Table 3). There was incomplete agreement in T cell
responses between the two assays, likely reﬂecting differences in
antigen processing for endogenously delivered proteins versus added
synthetic peptides and assay sensitivity related to culture conditions.
Segregation of responses between symptomatic and asymptomatic
HSV-2pos cohorts
PBMCs from each subject were screened to determine if their
CD4þ and/or CD8þ T cells could be activated by antigens comprising
our HSV-2 proteomic library. A response was deﬁned as an IFN-γ level
that exceeded twice the background response to irrelevant antigen
controls, corresponding to a 95% conﬁdence interval. Fig. 3 shows the
frequency of T cell responses for HSV-2pos subjects to each of the HSV-
2 clones expressed in the proteomic library. When responses from
both CD4þ and CD8þ T cells are considered, eight out of 77 HSV-2
clones were recognized with a frequency of greater than 30%,
including US12 (ICP47), RL2 (ICPO), UL2, RL1 (ICP34.5), UL15, N-
terminal fragment of RS1 (ICP4; RS1.1), UL11, and UL1 (gL). T cell
responses were detected to the remaining 69 HSV-2 clones expressed
in the library with frequencies ranging from 8% to 28%. Spearman
rank correlations were calculated to assess the relationship between
CD4þ and CD8þ T cell responses to HSV-2 antigens in the library.
Table 1
Demographic proﬁles of HSV seropositive and seronegative subjects.
HSV-2pos HSV-2neg
Symptomatic Asymptomatic HSV-2 Exposed Unexposed
Total subjects (n) 52 40 37 18
Age (yr)
Median (Range) 38 (20–72) 34 (22–65) 38 (19–71) 29 (18–60)
Gender (no. (%))
Male 15 (29%) 15 (39%) 19 (54%) 6 (33%)
Female 37 (71%) 25 (61%) 18 (46%) 12 (67%)
Race (no. (%))
White 42 (81%) 34 (83%) 31 (84%) 16 (89%)
Black 10 (19%) 6 (17%) 6 (16%) 2 (11%)
Recurrences/year
Median (SD) 5 (7) 0 0 0
Time from Dx (yr) – –
Mean (SD) 11.6 (10.8)a 2.9 (4.3)b
Range (yr) 0.5–36 0.5–19
HSV-1pos (no. (%)) 0 0 23 (62%) 9 (50%)
HSV-1neg (no. (%)) 52 (100%) 40 (100%) 14 (38%) 9 (50%)
a N¼47.
b N¼21.
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A strong correlation (r¼0.4960; po0.001) is observed if CD4þ and
CD8þ T cell frequencies for all 77 ORF pairs are taken into account
(Supplementary Fig. 1A). However, if only frequencies above 12% are
used, then there is no positive correlation (r¼0.2692; p¼0.1022).
To deﬁne if responses to speciﬁc HSV-2 antigens were corre-
lated with symptom control in HSV-2-infected subjects (all HSV-
1neg), the frequencies of T cell responses to each of the HSV-2
proteins were compared between the symptomatic and asympto-
matic HSV-2pos cohorts. The most frequently recognized antigen
for CD4þ T cells in the symptomatic cohort was RS1 (ICP4, two
fragments, RS1.1 and RS1.2; Fig. 4A), but there were no real stand-
out antigens in the asymptomatic cohort (Fig. 4B). UL11, US6 (gD),
US10 and US12 (ICP47), were the most frequently recognized
antigens by CD4þ T cells in the asymptomatic cohort, with a
responder rate of just over 15% for each. A greater number of
antigens were recognized with a frequency of over 15% in the
symptomatic cohort, namely RL1 (ICP34.5), RL2 (ICPO), UL2, UL15,
UL21, UL22 (gH), UL37, UL40, UL43, US12 (ICP47), and RS1 (ICP4)
(Fig. 4A). By this analysis, there was no CD4þ T cell antigen(s) in
the asymptomatic cohort that could be used to differentiate
“protected” versus “unprotected”. To avoid any bias imposed by
an arbitrary 15% cutoff for nomination of immunogenic antigens,
we also compared the absolute difference in the percent of
positive responders to each HSV-2 protein in the library in the
asymptomatic cohort compared to the symptomatic cohort. Forty-
ﬁve of 77 (58%) proteins were more frequently recognized by
CD4þ T cells in the symptomatic cohort relative to the asympto-
matic cohort (Fig. 4C).
In contrast to the CD4þ T cell responses, when comparing
CD8þ T cell speciﬁcities between cohorts, there was a greater
breadth of response in the asymptomatic cohort, with higher
frequency responses to the majority of antigens, and at least one
subject responding to every protein. The most frequently recog-
nized antigen for CD8þ T cells in the symptomatic cohort was
RL1 (ICP34.5) (Fig. 5A), and in the asymptomatic cohort, US12
(ICP47) (Fig. 5B). Ten proteins induced CD8þ T cell responses in
greater than 15% of subjects in the asymptomatic cohort
(Fig. 5B); speciﬁcally, RL1 (ICP34.5), RL2 (ICP0), UL2, UL3, UL22
(gH), UL40, UL46 (VP11/12), UL52, US12 (ICP47) and RS1.1 (ICP4
fragment). With the exception of RL1 (ICP34.5), RL2 (ICPO) and
US12 (ICP47), the remaining seven proteins were unique to the
asymptomatic cohort using this cutoff. In the symptomatic
Fig. 1. Anti-HSV-2 gD2 and neutralization antibody titers. (A) ELISA for anti-gD2 endpoint antibody titers. An ELISA titer r250 is deﬁned as negative, indicated by the
horizontal dotted line. (B) HSV-2-neutralizing antibody titers in plasma samples from subjects representing each of the four main cohorts. A neutralizing antibody titer r25
is deﬁned as negative, indicated by the horizontal dotted line. Each symbol corresponds to the titer of one subject; the horizontal line indicates the median titer for the
cohort. P-values were determined using an unpaired Student's t-test.
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cohort, only six proteins were recognized by more than 15% of
subjects (Fig. 5A): RL1 (ICP34.5), RL2 (ICP0), UL1 (gL), UL11,
UL15, and Us12 (ICP47).
In contrast to the CD4þ T cell frequency differences between
cohorts (Fig. 4C), the frequencies of CD8þ T cell responses for two-
thirds of the HSV-2 proteins or their fragments (52 of 77) are
Fig. 2. (A) Expression level of HSV-2 library clones relative to the positive control as determined by the B3Z assay described in the materials and methods. Data are shown as
the OD570 for each well divided by the OD570 produced in response to positive control SIINFEKL peptide. Library clones with a decimal following the HSV-2 gene designation
(e.g. UL32.1 and UL32.2) represent two overlapping fragments, comprising the full-length protein. (B) Schematic overview of the library screening platform employed for the
identiﬁcation of HSV-2 T cell antigens. Monocyte derived dendritic cells (MDDC) seeded in 96-well plates are pulsed with a thawed aliquot of either the library expressing or
lacking cLLO to screen CD8þ or CD4þ T cells, respectively. After 24 h, supernatants are collected and assayed for the presence of IFN-γ by ELISA. Library clones expressing the
antigens recognized by T cells induce secretion of IFN-γ (blue box). Controls include non-speciﬁc PHA-mediated stimulation of T cells (green box) and IFN-γ standards (red
box), which are included on each ELISA plate. (C) Representative example of CD8þ T cell responses from one donor. MDDC derived from an HSV-2pos asymptomatic donor
were added to plates previously seeded with an aliquot of the thawed library co-expressing cLLO. CD8þ T cells obtained from the same donor were then co-cultured with the
library-pulsed MDDC, as described in materials and methods and IFN-γ production in response to each clone was determined by ELISA. nHSV-2 genes that were initially
cloned as two fragments. T cells treated with PHA or GFP-expressing E. coli served as positive and negative controls, respectively. Data are shown as the mean IFN-γ response
of duplicates. The PHA response was 41500 pg/ml (not indicated on the graph). (For interpretation of the references to color in this ﬁgure legend, the reader is referred to
the web version of this article).
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higher in the asymptomatic cohort compared to the symptomatic
cohort (Fig. 5C; po0.0001, Kolmogorov–Smirnov test). These
results suggest that CD8þ and not CD4þ T cell responses are
associated with limiting symptomatic disease. These data can also
be interpreted to suggest that a greater breadth of responses from
CD8þ T cells is associated with control of symptoms.
Characterization of T cell responses from HSV-2-exposed HSV-2neg/
HSV-1pos and HSV-double-seronegative individuals
Although differences in responder frequencies to speciﬁc anti-
gens were apparent between symptomatic and asymptomatic
individuals, previous studies have demonstrated that some HSV-
2-exposed individuals who remain HSV-seronegative (HSV-2neg)
generate T cell responses to viral antigens (Posavad et al., 2010,
2003). One hypothesis is that these individuals have mounted T
cell-mediated protective immunity. Therefore, the comparison
of the frequency of responses to speciﬁc antigens from the
exposed uninfected cohort with the infected, symptomatic cohort
could yield the identiﬁcation of protein antigens that are most
correlated with protection. A representative CD4þ and CD8þ T cell
library screen for an exposed HSV-2neg subject is shown in
Supplementary Fig. 2. In the exposed HSV-2neg cohort, the highest
frequency responses to a subset of antigens are mediated by CD8þ
T cells, with 15% or more of the subjects responding to 15 antigens,
including nine proteins to which greater than 20% of the subjects
responded (Fig. 6A), compared to the symptomatic HSV-2pos
cohort in which 15% or more of the subjects responded to
6 antigens and only one clone, RL1 (ICP34.5), induced CD8þ T cell
responses with a frequency of greater than 20% (Fig. 5A). Analysis
of the difference in frequency between the CD8þ T cell responses
of the exposed HSV-2neg and symptomatic HSV-2pos cohorts
reveals 39 antigens (51%) with greater frequency responses in
the exposed compared to symptomatic cohort (Fig. 6B). The
antigen with the greatest difference in frequency of CD8þ T cell
response was RS1.1 (ICP4 fragment), with almost 20% more
subjects responding to this antigen in the exposed cohort than
in the symptomatic cohort.
When comparing CD4þ T cell responses, there were greater
frequencies of responses measured overall in the symptomatic
HSV-2pos cohort (Fig. 4A), with twelve clones recognized with a
frequency greater than 15% as opposed to two in the exposed HSV-
2neg group (Supplementary Fig. 3A). In contrast to the CD8þ T cell
results, CD4þ T cell responses were measurable to all of the clones
in the library in both the exposed and symptomatic HSV-2pos
cohorts, with the exception of UL35, to which there was no
detectable response in the exposed HSV-2neg cohort. When com-
paring the difference in frequency of response to each clone, there
were only 14 clones (18%) that were more often recognized in the
exposed HSV-2neg cohort, but the differences were quite small,
under 5% (Supplementary Fig. 3B); in contrast, there were 59
clones (77%) that were recognized with greater frequency in the
symptomatic HSV-2pos cohort, with differences ranging from one
to 15%. The differences in distributions between T cell phenotypes
were statistically signiﬁcant (po0.0001, Kolmogorov–Smirnov
test).
By our enrollment criteria, the HSV-2pos subjects could not be
co-infected with HSV-1. In contrast, the HSV-2neg subjects
recruited into this study could be either HSV-1 seropositive
(HSV-1pos) or negative (HSV-1neg). HSV-1 and HSV-2 share con-
siderable amino acid identity, which is one possible explanation
for why T cells that recognize HSV-2 antigens were found in
exposed HSV-2neg/HSV-1pos individuals. Therefore, we examined if
any of the HSV-2 library clones were capable of stimulating
measurable T cell responses in exposed HSV-double seronegative
(HSV-2neg/HSV-1neg) subjects. CD8þ T cell screens identiﬁed nine
viral antigens that were recognized by greater than 15% of the
exposed HSV-2neg/HSV-1neg subjects (Fig. 6C). The most frequently
recognized CD8þ T cell antigens were RL1 (ICP34.5), RL2 (ICPO),
UL1 (gL), UL11, UL21, UL36 (ICP1/2), UL44 (gC), UL49.5 and US12
(ICP47). The most frequently recognized CD4þ T cell antigens were
the N-terminal fragment of ICP4 (RS1.1), UL40, UL43 and UL54
(ICP27) (Supplementary Fig. 3C).
Comparison of magnitudes of T cell responses to HSV-2
antigens in protected versus unprotected cohorts
We next considered if control of infection or symptomatic
disease could be attributable to differences in the magnitude of
responses to speciﬁc antigens between cohorts, rather than
differences in frequency. Although the expression level of each
of the clones in the library is not normalized, since every
subject's T cells are screened against identical copies of the
library, the magnitude of their responses can be compared on a
clone-by-clone basis. To this end, the level of IFN-γ secretion
across each cohort in response to individual HSV-2 clones was
compared. The median IFN-γ values from each “unprotected”
cohort were subtracted from those obtained for the “protected”
Fig. 3. Frequency of T cell responses for HSV-2pos subjects to each clone in the library. CD4þ and CD8þ T cells from each donor were separately screened against the full
proteomic library using autologous MDDC, and levels of IFN-γ in the supernatants determined by ELISA. The indicated frequencies represent the number of positive
responses (IFN-γ level that is twice background) over the total number of subjects screened against each clone within the HSV-2 library. Data are presented as stacked bars,
with frequency of responses to each clone from HSV-1neg/HSV-2possubjects (N¼92). CD8þ T cells in red (N¼83) CD4þ T cells in blue (N¼85). For some of the subject's
PBMCs, we were not able to isolate enough CD14þ cells to prepare MDDC for screening of both of the subjects' CD4þ and CD8þ T cell populations. (For interpretation of the
references to color in this ﬁgure legend, the reader is referred to the web version of this article).
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cohort for each clone, and the antigens were ranked according to
the greatest difference in magnitude of response (data not
shown). A comparison of exposed HSV-2neg/HSV-1neg (protected)
and the HSV-2pos symptomatic cohort with Z4 outbreaks per
year (unprotected) is shown in Supplementary Fig. 4. For this
pairwise comparison, there were 12 CD8þ T cell antigens that
elicited greater magnitude (a difference greater than zero) IFN-γ
responses from exposed HSVneg individuals than symptomatic
HSV-2pos subjects. The differences in magnitude were statisti-
cally signiﬁcant for UL1 (gL) and RL2 (ICP0). This process was
repeated for multiple pairwise comparisons of “unexposed”,
“protected” and “unprotected” cohorts, and those clones that
consistently induced a high difference were selected for further
evaluation.
Supplementary Table 4 shows the top 20 antigens for each
comparison, ranked by the greatest magnitude of the difference in
cytokine level secreted in response to each antigen between the
cohorts. For the CD8þ T cell subset, only UL1 was ranked in the top
ten in all eight of the comparisons shown. Our hypothesis is that
consistency of differences in multiple comparisons increases the
robustness of our conclusions. As a result of these multiple
comparisons, nine T cell antigens were prioritized based on the
antigen being identiﬁed as important in Z three separate analyses
(Fig. 7). Three antigens were prioritized due to CD8þ T cell
responses exclusively. They are UL1 (gL), RL2 (ICP0), and UL21.
No antigens were selected based solely on CD4þ T cell responses;
however, the other six antigens, RS1.1 (N-terminal fragment of
ICP4), RS1.2 (internal fragment of ICP4), UL2, UL11, UL40, and US12
Fig. 4. Frequency and difference of frequencies of antigen-speciﬁc IFN-γ responses by CD4þ T cells derived from HSV-2 infected (HSV-2pos), symptomatic versus
asymptomatic cohorts. Library screens were performed as described. Frequencies represent the proportion of individuals within each cohort deﬁned as a responder (two-
fold over background) to a speciﬁc protein within the HSV-2 library. The dotted line indicates a response rate of 15%. CD4þ T cell responses from (A) Symptomatic (N¼48),
and (B) Asymptomatic (N¼37) cohorts are indicated. (C) Differences of CD4þ T cell frequencies. The values shown represent the absolute difference of the percent of positive
responders in the asymptomatic cohort minus the frequency of responders in the symptomatic cohort for each clone
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(ICP47) were prioritized based on both CD4þ and CD8þ T cell
responses.
RS1.1 and UL40 were in the top ten ranking for six of the
comparisons, and if the top 20 were taken into consideration, they
were high ranked for all eight comparisons (Supplementary
Table 4). The other top-ranked antigens (top twenty in four or
more comparisons) by this analysis were UL11, RL2 (ICPO), RS1.2
(truncated ICP4), UL2, UL21 and UL53. When compared to the
CD8þ T cell subset, the CD4þ T cell subset had fewer differences
greater than zero, and the magnitude of the differences were
much lower overall. Nevertheless, RS1.1 was among the top ten
rankings for seven of eight comparisons. The other antigens that
were ranked among the top twenty in four or more comparisons
were US8 (gE) and Us4 (gG) (each with ﬁve) and UL2, UL53, UL4,
UL40 and US12 (ICP47) (each with four).
If only those antigens that had statistically signiﬁcant differ-
ences (po0.05 by Wilcoxon Rank Sum test) in pairwise compar-
isons of the magnitude of protected versus unprotected cohorts’
T cell responses are considered, Supplementary Table 5, there
were seven proteins that yielded signiﬁcance in three or more
comparisons from the CD8þ T cell subset: RS1 (all three fragments
of ICP4), UL1 (gL), RL2 (ICP0), UL36, UL49A, UL21, and UL4. Three
proteins yielded signiﬁcance in two comparisons: UL34, UL49,
and UL53. No proteins were signiﬁcant in more than three
comparisons from the CD4þ T cell subset. Three antigens were
signiﬁcant in two comparisons; they were RS1.1 (N-terminal
fragment of ICP4), UL32, and UL33. Only one antigen, RS1.1
(ICP4), was identiﬁed as signiﬁcant in both CD8þ and CD4þ T cell
subsets, whereas UL32 and UL33 was signiﬁcant for only the CD4þ
T cell subset.
Discussion
Here we report the identiﬁcation of multiple viral antigens that
are associated with control of recurrent HSV-2 genital disease and/
or infection in human subjects. CD4þ and/or CD8þ T cell recall
responses to UL1 (gL), UL21, RS1 (ICP4), RL2 (ICP0), US12 (ICP47),
UL2, UL11, and UL40, were overrepresented by frequency and/or
magnitude of response, in individuals who control their disease or
Fig. 5. Frequency and difference of frequencies of antigen-speciﬁc IFN-γ responses by CD8þ T cells derived from HSV-2 infected (HSV-2pos), symptomatic versus
asymptomatic cohorts. Library screens were performed as described. Frequencies represent the proportion of individuals within each cohort deﬁned as a responder (two-
fold over background) to a speciﬁc protein within the HSV-2 library. The dotted line indicates a response rate of 15%. CD8þ T cell responses from (A) Symptomatic (N¼45),
and (B) Asymptomatic (N¼38) cohorts are indicated. (C) The values shown represent the absolute difference of the percent of positive responders in the asymptomatic
cohort minus the frequency of responders in the symptomatic cohort for each HSV-2 clone.
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remain uninfected after exposure (Fig. 7). If the observed correla-
tions accurately predict the capacity of these antigens to activate
protective T cells, they may be good candidates for inclusion
in a therapeutic or prophylactic HSV vaccine. Recently, we demon-
strated that vaccination of HSV-2 infected guinea pigs with a
truncated form of ICP4 (RS1.2) signiﬁcantly reduced recurrent
lesion outbreaks (Skoberne et al., 2013).
There is a large body of evidence that both CD4þ and CD8þ T
cells are important in host defense against HSV-2 in both prophy-
lactic and therapeutic settings (Cunningham et al., 2006; Koelle
and Corey, 2003; Nakanishi et al., 2009). Vaccines that have
entered clinical trials to date have primarily induced antibody
responses and have been inconsistent in their ability to protect
against genital herpes disease or have failed. A prevailing theory is
that the failures were attributable to the absence of a sufﬁciently
strong T cell component in the vaccine formulation (Cohen, 2010;
Mascola, 1999). Indeed, one main risk factor for recurrent severe
HSV disease is T cell deﬁciency, but not agammaglobulinemia
(Koelle and Corey, 2003; Whitley et al., 1984). In addition, while
antibody may provide some protection to neonates (Brown et al.,
1991), and recently antibody concentration was associated with
preventing HSV-1 genital disease and infection in gD2 vaccine
immunized HSV-seronegative women, there is minimal evidence
that antibody alone is effective against acquisition of HSV-2 genital
disease (Belshe et al., 2012, 2013), or virus reactivation and
recurrent disease (Spruance et al., 1995). This observation was
nicely characterized in a study of patients with a history of
frequent recurrences who had higher median serum antibody
titers to HSV that were coincident with lower HSV-2-speciﬁc IFN-γ
and IL-2 production from PBMC (Spruance et al., 1995).
The nature of T cell immunity is critical to mediating protec-
tion. IFN-γ is an important mediator of resistance to infection and
reactivation. Previous studies have demonstrated that HSV-speciﬁc
IFN-γ secretion is impaired in some subjects who have recurrent
symptomatic disease (Green et al., 1985) and show that higher
levels of IFN-γ secreted in response to a recurrence is correlated
Fig. 6. Frequencies of antigen-speciﬁc IFNγ responses by CD8þ T cells derived from the exposed HSV-2neg cohort, and comparison with frequencies in the symptomatic, HSV-
2pos cohort. The fraction of exposed HSV-2 neg subjects who responded with a (A) CD8þ T cell response to each antigen in the library is indicated. A response was deﬁned as
IFNγ concentration reaching greater than twice background. The dotted line indicates a cutoff of a 15% response rate. (B) The difference in frequencies of response between
the exposed (HSV-2neg), versus infected (HSV-2pos), symptomatic cohorts are indicated for each clone. The values shown represent the absolute difference of the percent of
positive responders in the exposed HSV-2neg (N¼31) minus the frequency of responders in the symptomatic cohort (N¼45) for each HSV-2 clone. (C) HSV-2 proteins
recognized by CD8þ T cells derived from exposed HSV-2neg/HSV-1neg subjects (N¼12 of 14). The frequency is calculated as the number of subjects with a response that
exceeded 2X the background over the total number of subjects in the cohort. Where no bar is indicated, no response was measured. The dotted line indicates a cutoff of 15%.
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with increased time to next recurrence (Cunningham and Merigan,
1983). In the case of exposed individuals that do not seroconvert
but mount a cellular immune response, as described by Posavad
et al., and in this study, we hypothesize that IFN-γ is also important
for resistance to infection. Animal models have demonstrated that
effector CD8þ T cells surround HSV-1-infected ganglia and control
latency; they also surround nerve termini in HSV-2 infected genital
epithelium and complement CD4þ T cells in viral clearance from
genital lesions (reviewed in Laing et al., 2012). Recently unique
tissue-resident effector memory T cells have been deﬁned that are
CD8ααþ T cells, reside at the dermal–epidermal junction after the
classical CD8αβþ T cells disappear, and may function as sentinel
cells that can mediate rapid clearance of virus upon reactivation
(Zhu et al., 2013). The antigenic speciﬁcity of these unique cells are
yet to be deﬁned, but they may be a mechanism for control of
reactivation, symptoms should reactivation occur, or both.
There are multiple challenges associated with identifying
protective T cell antigens from diverse human donors, ranging
from human genetic diversity to the abundance of potential T cell
antigens from any given pathogen (Grubaugh et al., 2013). We
have been able to evaluate both CD8þ and CD4þ T cell responses,
their speciﬁcity and their magnitude, with our unique technol-
ogy. Because of the low abundance of HSV-speciﬁc CD8þ T cells
in human blood we utilize anti-CD3/anti-CD28 beads to non-
speciﬁcally expand enriched T cell subsets from PBMCs prior to
HSV-2 library screening. It is possible that non-speciﬁc expansion
of T cells could alter (gain or lose) some antigen speciﬁcities but
studies have demonstrated that expansion by anti-CD3/anti-
CD28 is polyclonal and can preserve T cell immune function
(Teschner et al., 2011). Another method used to expand human
HSV-speciﬁc T cells for downstream testing was recently reported
by Jing et al. (Jing et al., 2012). They demonstrated that initial
stimulation of T cells, either cross-presentation for CD8þ T cells
or UV-inactivated virus stimulation for CD4þ T cells, followed by
CD137 activation-based FACS selection effectively enriches HSV-1
speciﬁc T cells prior to nonspeciﬁc mitogen expansion for down-
stream testing.
We used a cohorting strategy to classify patients into “pro-
tected” and “unprotected” groups based on their ability to resist
known exposure (exposed or discordant couples), control an initial
symptomatic infection (asymptomatic) or recurrent disease. We
ﬁnd that a major distinguishing feature of the “protected” cohorts
is that they have mounted broader and higher CD8þ T cell
responses, measured systemically, than cohorts who suffer from
recurrent infections. The different comparisons between various
protected and unprotected groups yielded generally consistent
differences in the antigens targeted most often and at the highest
magnitude. Since that is the case, we can infer that optimal
immune targets for protection and control of existing disease
may be similar or at least overlap to some degree.
Fig. 7. Prioritization of HSV-2 antigens based upon the consistency with which they were top-ranked through eight separate analyses. Antigens that were determined to be
priority targets for CD4þ and CD8þ T cell subsets through each analysis were compiled. Black bars represent prioritization based on CD8þ T cell responses and open bars
represent prioritization based on CD4þ T cell responses. Eight separate analyses were performed with each T cell subset: overall frequency (Fig. 3), frequency 415% in
asymptomatic vs. symptomatic comparison (Figs. 4A and B, 5A and B), difference in frequency 410% in asymptomatic vs. symptomatic (Figs. 4C, 5C), Frequency 415% in
exposed vs. symptomatic comparison (Fig. 6A, Supplementary Fig. 1A), difference in frequency 410% in exposed vs. symptomatic comparison (Fig. 6B, Supplementary
Fig. 1B), frequency 415% in exposed double seronegative (Fig. 6C, Supplementary Fig. 1C), top-ranked magnitude difference in IFN-γ secretion in more than four “protected”
minus “unprotected” comparisons (Supplementary Fig. 2, Table 1, and data not shown), antigens with statistically difference in magnitude between “protected” and
“unprotected” cohorts (Supplementary Table 3).
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Seventy-ﬁve unique antigens of HSV-2 were ranked using the
difference in speciﬁcities and magnitude of CD8þ T cells primarily,
but also CD4þ T cells, between our protected and unprotected
cohorts. Based on the analysis we selected the 7 top HSV-2
antigens to further characterize as vaccine candidates. UL1 (gL),
UL11, and UL21 are virion structural proteins, whereas UL2, RS1
(ICP4), RL2 (ICP0) and US12 (ICP47) are all nonstructural proteins.
Three of the nonstructural proteins, ICP4, ICP0 and ICP47, are
characterized as immediate early (IE) proteins which are the ﬁrst
to be expressed following infection. IE proteins are plausible
therapeutic vaccine targets, since T cell responses to these antigens
might enable early control of virus reactivation (Posavad et al.,
2010). The most frequently recognized antigen, irrespective of
cohort or T cell phenotype, was gL, encoded by UL1. It was also the
most frequently recognized antigen in the CD8þ T cell subset, with
the greatest frequency of responses in the exposed HSV-2neg/HSV-
1pos cohort, followed by approximately equal representation in the
HSV-2pos/HSV-1neg and exposed HSVneg cohorts. gL is found in the
virion envelope and exists as a heterodimer with gH; one partial
role for gL is to act as a chaperone for gH (Hutchinson et al., 1992).
The gH–gL complex is conserved in all three classes of herpes-
viruses, and along with gB and gD are essential for virus infectivity
and cell to cell spread (Spear, 2004). The previous studies looking
at gL as an immune target (often the gH/gL complex) were focused
on antibody. Those studies demonstrated that antibodies could
block viral entry, neutralize HSV-1, reduce primary lesions, and
eliminate secondary zosteriform lesions in a zosteriform model
(Peng et al., 1998). However, immunization with baculovirus
expressed gL failed to protect mice in a separate study using lethal
intraperitoneal or ocular challenge with HSV-1. In those studies,
the mice produced serum antibodies speciﬁc for gL but they were
non-neutralizing (Ghiasi et al., 1994).
UL21 and UL11 are part of a complex with a third tegument
protein UL16 on the cytoplasmic tail of glycoprotein E (Chadha et
al., 2012; Han et al., 2012). UL11 is a small protein associated with
the internal (cytoplasmic) membrane, plays a role in nucleocap-
sid envelopment and egress, and appears to trafﬁc between the
plasma membrane and the golgi apparatus (Loomis et al., 2001).
UL21 is a protein associated with the capsid transport in the
cytoplasm, and interacts with UL11 only indirectly through UL16
(Harper et al., 2010). To our knowledge, neither UL11 nor UL21
have been evaluated as vaccine targets for HSV-2 immunother-
apy or prophylaxis. UL21 was previously described as a T cell
target in CD4þ T cells inﬁltrating a genital HSV-2 herpes lesion in
a human subject and also in a subject with herpes stromal
keratitis, but the cell line speciﬁc for this antigen was non-
cyototoxic to HSV-2 infected target cells (Koelle et al., 1998,
2000a, 2000b).
The IE proteins RS1 (ICP4), which is a major activator of HSV-2
transcription (Wagner et al., 2013, 2012) and RL2 (ICP0), which is a
viral IFN antagonist that modulates the host ability to repress HSV
replication (Halford et al., 2013), were recognized by CD8þ T cells
derived from both asymptomatic HSV-2pos and exposed HSV-2neg
individuals. These antigens were also identiﬁed as CD8þ T cell
antigens in HSV-2 exposed, immune seronegative subjects by
Posavad et al. (Posavad et al., 2010, 2003). They theorized that T
cells directed against IE proteins would prove especially advanta-
geous to the host because they 1) kill virally-infected cells before
the generation of infectious progeny, and 2) provide a quick
defense against spreading infection via localization to the reacti-
vation site. Indeed, this premise could explain why no HSV DNA
was detected at mucosal sites in exposed HSV-2 seronegative
subjects. Alternatively, antigen-speciﬁc T cell responses identiﬁed
in HSV-seronegative individuals may be explained by cross-
reactivity with T cell targets for other herpesviruses (Chiu et al.,
2014; Ouwendijk et al., 2014).
Further studies are needed to determine if T cells directed
against IE proteins home to sites of HSV-2 exposure in HSV-2
immune seronegative subjects. However, preclinical data from
guinea pigs immunized therapeutically with a subunit vaccine
containing a fragment of ICP4 (called ICP4.2 or RS1.2) in combina-
tion with a gD deletion mutant (gD2ΔTMR) resulted in signiﬁcant
reduction in the frequency of viral shedding in immunized animals
compared to controls, suggesting that immune responses directed
to ICP4 are impacting viral reactivation (Skoberne et al., 2013).
UL2 encodes a uracil DNA glycosylase (UNG) implicated in DNA
repair, is highly conserved among herpesviridae and is fairly
conserved between HSV-2 and human nuclear-encoded UNG, with
over 40% amino acid identity. In mammals, this protein is impli-
cated in class switch recombination and somatic hypermutation.
Given the conservation, it is curious that this is an antigen for
putatively protective human T cell responses to HSV-2. However,
its use as a vaccine candidate comes into question with the risk of
developing autoimmunity and possibly increasing the risk of B cell
malignancies (Andersen et al., 2005).
The IE protein ICP47, encoded by US12, is an immune evasion
protein secreted by the virus. It is surprising that we ﬁnd robust T
cell responses to this antigen given its role as an inhibitor of the
transporter associated with antigen presentation (TAP), which in
turn blocks CD8þ T cell responses (Goldsmith et al., 1998; Hill et
al., 1995). HSV-1-encoded ICP47 was evaluated previously as a
vaccine candidate. Immunization with ICP47 encoded by a vaccinia
vector failed to protect against lethal HSV-1 challenge despite
signiﬁcant T cell proliferation in response to immunization (Banks
et al., 1994; Hill et al., 1995).
The antigens identiﬁed in this study do not completely overlap
with other published data in which, in addition to the surface
glycoproteins gD (US6) and gB (UL27), UL25, UL39, capsid protein
VP5 (UL19) the tegument proteins such as UL46, UL47, VP16
(UL48) (VP16), and VP22 (UL49) have been identiﬁed as CD4þ
and/or CD8þ T cell targets in HSV-infected individuals (Koelle et al.,
1998, 2000a, 2000b; Hosken et al., 2006; Kim et al., 2008; Zhu et al.,
2013). While each of these antigens was identiﬁed as a target of
T cell responses in our screens, none were prioritized based on
high frequency in the asymptomatic HSV-2pos or exposed unin-
fected cohorts. Previous studies have reported a CD4þ T cell
response rate to gD ranging from 68% to 100% in HSV-2 infected
subjects (Koelle et al., 2000a, 2000b; Kim et al., 2008) whereas in
our library screens, we observed a lower frequency of 15% to gD2.
Previous studies used restimulated CD4þ T cell lines as respon-
ders, which has the potential of preferential ampliﬁcation of T cell
responses to certain HSV antigens over others, in which case the
response rate to gD may be overestimated (Koelle et al., 2000a,
2000b). The evaluation of CD4þ T cell cytokine responses using
exogenous loading of peptides vs endogenous protein processing
is another likely explanation for differences observed in response
rates (Kim et al., 2008). Many of the elegant studies to identify
antigenic targets of T cells from HSV-2-infected individuals have
been focused on epitope-based discovery with limitations to the
number of subjects and number of human leukocyte antigen (HLA)
molecules that can be probed to identify responses. Using a
peptide-based approach and a similar exposed HSV-2neg cohort
as was recruited for this study, Posavad et al. (Posavad et al., 2003,
2010) demonstrated that T cell responses in immune seronegative
(IS) subjects were directed primarily to UL39 (ICP6) and the IE
proteins ICP4 (RS1) and ICP0 (RL2), although they also detected
responses to UL19 (ICP5) and UL29 (ICP8). With the exception of
the IE proteins, ICP4 (RS1) and ICPO (RL2), none of the other T cell
antigens were identiﬁed by our library screen as high frequency
targets in the exposed HSV-2neg cohort. In addition, compared to
the Posavad et al. study (Posavad et al., 2010) we observed a lower
T cell response rate in HSV-2pos subjects for gD2, gB2 and
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tegument proteins, UL46 and UL49. One explanation for differ-
ences in T cell response rates is that in this study the proteins were
processed by the natural processing machinery of each subjects’
own APC, in contrast to the Posavad studies where peptides were
exogenously loaded. Processing of endogenous antigens by APC
proteases and the proteasome are different, qualitatively and
quantitatively, to loading of APC with exogenous synthetic pep-
tides (Ayyoub et al., 2001).
The strength of the ATLAS™ technology is that it uniquely enables
screening for T cell responses, and in particular, speciﬁc activation of
the CD8þ T cell subset, using whole protein antigens. One limitation
to this approach is that proteins expressed in E. coli do not have the
same post-translational modiﬁcations as in virus infected cells; many
of the proteins are also expressed in inclusion bodies. What is
important, however, is that the amino acid sequences are intact such
that the appropriate T cell epitopes can be processed from the
expressed proteins by the peptide processing machinery of APCs. A
recent publication has shown that only a minimal number of epitopes
are N- or O-glycosylated (up to 2%; Szabo et al., 2009), for example,
and it is the case therefore, that we may miss T cells speciﬁc for a
glycosylated epitope. With ATLAS™, large numbers of genetically
diverse subjects can be screened in a high-throughput way. By
screening whole proteins, we allow the natural processing machinery
of each subjects’ APCs to process and present their own epitopes on
the cell surface for recognition by cognate T cells. In this way, the
process is predicted to avoid problems with HLA restrictions. Our
limited look at this question showed no HLA biases.
While this work was primarily focused on identifying novel T
cell antigens from HSV-2, we also explored antibody responses in
relation to disease outcome. In this study the highest anti-gD and
HSV-2 neutralizing titers were measured in the symptomatic HSV-
2pos donors when compared with asymptomatic HSV-2pos indivi-
duals. In addition, two subjects serotyped as HSV-1 and HSV-2
seronegative by HerpeSelect ELISA were antibody positive based
on a HSV-2 neutralization assay and gD2 ELISA. While data in an
animal model suggests that pan-HSV IgG maybe a correlate of
protection upon immunization (Halford et al., 2013), our data
imply that in natural HSV-2 infection in humans, antibody
responses are not necessarily responsible for controlling the
frequency of symptomatic recurrences, and conﬁrms the observa-
tions of others (Spruance et al., 1995). It is necessary to point out
that we cannot conclude that neutralizing antibodies do not play a
role in containing the disease. In fact, higher titers, higher afﬁnity,
and different neutralizing targets may help control/protect from
HSV. However, the data do support that T cells are required for the
control of recurrent HSV-2 genital disease.
In summary, we have described a T cell antigen identiﬁcation
system that uses E. coli to express the complete HSV-2 proteomic
library. This system was used to identify putatively protective
CD4þ and CD8þ T cell antigens from HSV-2 for immunological
studies or as components of prophylactic and therapeutic subunit
vaccines against a disease where no vaccine currently exists. The
ﬁndings presented here support the hypothesis that T cells derived
from “protected” individuals preferentially recognize different sets
of HSV-2 protein antigens compared to infected symptomatic
patients. They additionally suggest that it is the frequency,
breadth, and magnitude of CD8þ T cell responses that correlate
with positive outcomes. We have focused on characterizing the T
cell antigen repertoire of HSV cohorts rather than individuals and
demonstrated that the asymptomatic HSV-2pos cohort has broader
CD8þ T cell speciﬁcities, with 52 of 77 antigens having higher
frequencies than the symptomatic HSV-2pos cohort ( 23 of 77), and
the symptomatic cohort has broader CD4þ T cell speciﬁcities, with
45 of 77 antigens with higher frequencies than the asymptomatic
cohort (26 of 77). It is difﬁcult to attribute breath to protection,
however, breadth may simply be due to repeat exposure to the
virus; even asymptomatic subjects experience periodic reactiva-
tion. Interestingly, the exposed uninfected cohort had the most
limited breadth of response, suggesting that it is speciﬁcity of the
response and not the breadth that is critical for their theorized
protection from acquiring HSV-2 genital infection. The identiﬁca-
tion of HSV-2 T cell antigens associated with control of genital
infection or disease is an important step for studying T cell
immunity, vaccine development or pathogenesis research. A
clinical trial of a therapeutic vaccine made up of antigens identi-
ﬁed with these studies is currently ongoing; to test the hypothesis
that immune-redirecting toward robust T cell responses can result
in decreased viral shedding and decreased frequency and severity
of symptomatic recurrences.
Materials and methods
Cells and virus
B3Z T cell hybridoma cells, kindly provided by Dr. Nilabh
Shastri (UC Berkeley) (Karttunen et al., 1992), and RAW309 cells
(ATCC, Manassas, VA) were maintained in RPMI-1640 supplemen-
ted with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 1 mM
sodium pyruvate, 50 mM β-mercaptoethanol, 200 U/mL of penicil-
lin and 200 mg/mL of streptomycin. Vero cells (ATCC) were grown
in Dulbecco's Modiﬁed Eagle's Medium (DMEM), supplemented
with 10% FBS, 2 mM L-glutamine, 1 mM sodium pyruvate, and
penicillin/streptomycin. Herpes simplex virus type 2 (HSV-2)/Gal,
kindly provided by Dr. Patricia Spear (Northwestern University)
(Taylor et al., 2007), was propagated in Vero cells as previously
described (Skoberne et al., 2013). HSV2/Gal has a lacZ expression
cassette inserted between UL3 and UL4 genes.
Construction of pDEST-SL8 expression vector
The T7 terminator of pDEST17 (Invitrogen Life Technologies) was
ampliﬁed by PCR using the primers 50- GGGGGGCTAGCGATTCGA-
GGCTGCTAACAAAGC -30 and 50- GGGGGGAAGCTTGCGTTGA-
TGCAATTTCTATGCGCA -30. The PCR product and pDEST17 were
digested with NheI and HindIII. The 6.1 kb fragment of pDEST17 was
puriﬁed and ligated to the digested PCR product. The nucleotide
sequence for the SIINFEKL peptide epitope (Rotzschke et al., 1991) was
added in-frame to the attB2 sequence through two sequential PCR
ampliﬁcations. The ﬁrst PCR reaction ampliﬁed the attB2 site from
pDEST17, using the primers 50–GAACGGCTCTTTTGCTGACGAG- 30 and
50- TCTCAAGCTGCTCAAGGCCTGAGACACCACTTTGTACAAGAAAGCTG-
AACG -30. The PCR product was reampliﬁed with primers 50–GAA-
CGGCTCTTTTGCTGACGAG -30 and 50–GGGGGGCTAGCTTACAGTTTTT-
CAAAGTTGATTARACTCTCAAGCTGCTCAAG-30. The PCR product and
the vector from the initial ligation were digested sequentially
with NheI and SalI. The 6 kb fragment from the vector was ligated
to the digested PCR product, resulting in the pDEST-SL8 vector
(Gierhan, 2007).
Generation of the HSV-2 expression library
Primer 3 software (SimGene.com) was used to design primer
sets for amplifying the sequence of each annotated HSV-2 gene in
the genome (PubMed, NC_001798). In some cases, gene targets
were ampliﬁed as large overlapping fragments or synthesized by a
commercial source (DNA 2.0, Menlo Park, CA). The 50 end of
the forward primer was designed to be the ﬁrst nucleotide in
the exon, and the 50 end of the reverse primer was designed to
be complementary to the last nucleotide before the stop codon
in the sequence, removing the stop codon from each gene.
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50–ACAAAAAAGCAGGCTGC-30 was added to the 50 end of each
forward primer, and 50–ACAAGAAAGCTGGGTAG-30 was added to
the 50 end of each reverse primer. The primer sets used to amplify
each gene from HSV-2 G strain genomic DNA (Advanced Bio-
technologies, Columbia, MD) are shown in Supplementary Table 1,
without the linker sequences added. The resulting products were
then re-ampliﬁed with primers 50–GGGGACAAGTTTGTACAAA-
AAAGCAGGCTGC-30 and 50–GGGGACCACTTTGTACAAGAAAGCTGG-
GTAG-30, to add the attP cloning sequences to each product. BP
clonase (Life Technologies) was used to insert each PCR product
into pDONR211 (Invitrogen), according to the manufacturer's
protocol. Plasmids successfully transformed into E. coli strain Stbl2
were isolated using the 96-well PerfectPrep kit (Thermo Fisher
Scientiﬁc, Waltham, MA). Inserts cloned into pDEST-SL8 by LR
clonase (Life Technologies) were ﬁrst veriﬁed by ampliﬁcation
with primers 50–GTTGTAAAACGACGGCCAGTCTT-30 and 50–
GAGCTGCCAGGAAACAGCTATGA-30. Transformants were selected
with carbenicillin, and the plasmid for each clone was isolated. The
primers 50–TCTCGATCCCGCGAAATTAATACG-30 and 50–TCCGGATA-
TAGTTCCTCCTTTCAGC-30 were used to amplify the insert to ensure
the proper size. Following veriﬁcation of the insert, the vector was
transformed into E. coli strains BL21RAIL (Life Technologies) that
either did or did not also contain a separate plasmid encoding a
cytoplasmic variant of the Listeria monocytogenes cytolysin, lister-
iolysin O (cLLO), which is constitutively expressed (Higgins et al.,
1999). DNA sequencing revealed the correct ORF insert in each
plasmid when compared to the published HSV-2 strain HG-52
sequence (Dolan et al., 1998). E. coli library clones, with and
without cLLO, were grown in deep 96 well plates at 37 1C until
they reached a median OD600 between 0.14 and 0.20 and then
induced with arabinose as previously described (Mofﬁtt et al.,
2011). Each HSV-2 library clone was resuspended to a ﬁnal
concentration of 109/mL, ﬁxed with paraformaldehyde, aliquoted
into 96 well plates and frozen at -70 1C. This generated HSV-2
libraries co-expressing cLLO, for the screening of CD8þ T cells, and
not co-expressing cLLO, for the screening of CD4þ T cells. Co-
expression of cLLO with recombinant antigen has been shown to
stimulate class I-restricted CD8þ T cells following uptake by
human APC (Radford et al., 2002; Hu et al., 2004).
Validation of library expression
To evaluate expression levels, an aliquot of each library clone
was thawed and 50 mL added to RAW309 cells, seeded at a
concentration of 2106 cells/mL in a 96-well plate and incubated
for 1 h at 37 1C. The plates were washed and then B3Z cells were
added at 2106 cells/mL in cRPMI and incubated at 371C for 15–
20 h. As a positive control, the SIINFEKL peptide (GenScript,
Piscataway, NJ) was added at a ﬁnal concentration of 100 nM to
separate wells containing B3Z and RAW309 cells. After incubation,
the media was removed and replaced with 100 mL/well of Z-buffer
(154 mM chlorophenolred-β-D-galactopyranoside (CPRG) sub-
strate, 10 mM MgCl2, 0.125% NP-40, and 1 mM β-mercaptoethanol
in phosphate buffered saline (PBS)). The plates were allowed to
develop for 4–5 h at 37 1C, and the OD590 was measured.
Study population
One hundred forty seven individuals of varying HSV serology,
age, and gender were screened and recruited into the study. There
were three groups of subjects who had a history of genital HSV-2,
and were HSV-2 seropositive (HSV-2pos) and HSV-1 seronegative
(HSV-1neg). They could be further stratiﬁed into three groups: 1)
those having no recurrences, 2) 1–3 recurrences per year, or 3)
four or more recurrences per year. In addition, we recruited HSV-
2-exposed individuals, without specifying they be HSV-1neg, and
HSV-2neg controls who had no known exposure, who could also be
HSV-1pos or HSV-1neg. For some analyses we pooled groups
including the recurrent HSV-2 groups, and the exposed and
control group, when justiﬁed by the similar responses observed.
The study participants were recruited by advertising at 5 clinical
sites: Westover Heights Clinic in Portland, Oregon, University of
North Carolina (UNC) School of Medicine in Chapel Hill, Key
Biologics LLC in Memphis, TN, The Fenway Institute in Boston,
MA, and Research Blood Components in Brighton, MA. Enrollment
took place between April 2008 and April 2009. The Westover
Heights Clinic and UNC center recruited the majority of subjects
with 53% and 35%, respectively. Informed consent was obtained
from all subjects with Institutional Review Board approval
(Quorum IRB). HSV-1 and HSV-2 type-speciﬁc serology was
determined by the HerpeSelect IgG enzyme-linked immunosor-
bant assay (ELISA) kit (Focus Technologies, Cypress, CA). Demo-
graphic and clinical data were obtained from questionnaires and
medical records. HLA typing (American Red Cross, MA) was
performed on the ﬁrst 89 donor samples that had sufﬁcient cells
remaining for analysis.
Fractionation and isolation of CD4þ and CD8þ T cells, antigen
presenting cells (APC), and plasma
Peripheral blood mononuclear cells (PBMCs) were isolated
from heparinized venous blood by standard Ficoll-Paque Plus
(GE Healthcare, Uppsala Sweden) density centrifugation and were
cryopreserved at a concentration of approximately 1107 cells/
mL following standard protocols. The plasma fraction was col-
lected, and stored at 701C for use in antibody analysis by ELISA
and HSV-2 neutralization assays.
Thawed PBMC were enriched for CD4þ and CD8þ T cell
subsets, and CD14þ monocytes by positive selection, using mag-
netic bead isolation (Miltenyi Biotec, Auburn, CA). To drive
differentiation of monocytes into dendritic cells (MDDC), they
were cultured with 300 U/mL recombinant human granulocyte-
macrophage colony-stimulating factor (rGM-CSF) and 400 U/mL
interleukin (rIL)-4 (Becton, Dickinson and Company, NJ) for 7 days.
MDDC were harvested with PBS containing 3% FBS and 0.5 mM
EDTA, washed, and resuspended at 2106 cells/mL in T cell media
(TCM) containing 43% α–MEM, 43% RPMI-1640, 10% FBS, 1% non-
essential amino acids (NEAA), 1 mM sodium pyruvate, 25 mM
HEPES, 2 mM L-glutamine, 50 mM β-mercaptoehanol, 100 U peni-
cillin and 100 mg/mL streptomycin.
Enriched CD4þ or CD8þ T cells were non-speciﬁcally expanded
at 37 1C using anti-CD3/–CD28 Dynabeadss (Invitrogen, Grand
Island, NY), according to the manufacturer's instructions. T cell
cultures were maintained at a concentration of 0.5–1106 cells/
mL; after 3 days, 20 U/mL of rhIL-2 was added. After 7 days in
culture and 24 h prior to library screening, the Dynabeadss were
removed and T cells resuspended at 1106 cells/mL in cAIM-V
media (AIM-V supplemented with 5% FBS, 1% NEAA, 2 mM L-gluta-
mine, 1 mM sodium pyruvate, and 50 mM β-mercaptoethanol).
HSV-2 library screening
A 50 mL aliquot of each bacterial clone from the HSV-2 E. coli
libraries (with and without cLLO) was added to a 96 well tissue
culture plate containing MDDCs, seeded at a density of 1105
cells/well, and incubated for 2 h at 371C. After centrifugation, the
media was removed and the cells were ﬁxed in 1% paraformalde-
hyde for 10 min at room temperature, neutralized with 120 mM
lysine and washed extensively with PBS. CD4þ T cells were added
to plates (1105 cells/well) pulsed with library clones without
cLLO and CD8þ T cells (1105 cells/well) were added to the wells
pulsed with cLLO-containing clones. Cells were cocultured for 24 h
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at 371C then supernatants harvested and stored at 201C until
evaluated for IFN-γ concentration by ELISA (OptEIA IFN-γ ELISA, BD
Biosciences, San Jose, CA) following manufacturer's instructions.
Cell-based assays were performed in singlicate, and ELISA assays
were performed in duplicate. Intracellular staining and ﬂow
cytometry were used to verify a limited number of subject's
responder cells used in the library screen as CD4þ or CD8þ T cell
phenotype (data not shown).
Anti-glycoprotein D (gD) IgG ELISA and HSV-2 neutralizing antibody
titers
Antibody titers against gD were determined by endpoint ELISA,
as described previously (Skoberne et al., 2013). Brieﬂy, ELISA plates
were coated at 0.5 mg/mL with a puriﬁed baculovirus recombinant
gD2 lacking the 25aa transmembrane region and incubated over-
night at 41C (Skoberne et al.,2013). Plasma samples, serially-
diluted three-fold, were incubated in 1% bovine serum albumin
blocked gD-coated wells, and anti-gD antibody was detected using
alkaline phosphatase (AP)-conjugated anti-human IgG (Sigma-
Aldrich, St. Louis, MO), and SIGMAFAST™ p-Nitrophenyl-
phosphate (pNPP; Sigma-Aldrich) substrate. The resultant optical
density (OD405) was plotted against the sample dilution (log10) and
the regression line representing the best ﬁt for the data was
calculated via GraphPad Prism and Microsoft Excel software. The
endpoint titer was deﬁned as the reciprocal of the serum dilution
resulting in an OD405 equal to twice the background.
Antibody-mediated neutralization of HSV-2/Gal infectivity was
determined via a β-galactosidase (β-gal) colorimetric assay, as
described previously (Skoberne et al., 2013). The resultant optical
density was measured at 590 nm, and neutralizing antibody titer
was deﬁned as the reciprocal of the plasma or serum dilution that
produced a 50% reduction in the OD590 of the virus control.
Data analysis and statistical methods
Analyses performed on CD4þ and CD8þ T cell subset data
included: 1) determination of the frequency of responders in each
cohort to each HSV-2 antigen, 2) evaluation of the highest median
absolute response for a given protein in the “protected” cohorts,
and 3) the greatest magnitude of difference in response between
“protected” vs. “unprotected” cohort groups.
The frequency of responders (% of responders) within each
cohort was determined by comparing induction of IFN-γ in
response to each HSV-2 protein with responses to the negative
control, green ﬂuorescent protein (GFP), also present in the library.
After log transformation to normalize the data, a “response” was
deﬁned as a two-fold increase in cytokine concentration over the
negative control, the equivalent of approximately two standard
deviations above the mean of the negative control response. One-
tailed Wilcoxon Rank Sum tests were used for analysis of differ-
ences in magnitude of responses between cohorts.
To determine if an HLA supertype was over-represented in any
clinical cohort, individual Chi Squared tests were performed using
two variables: 1) group “protected” or “unprotected” (exposed or
symptomatic) and 2) HLA types (present or absent).
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